Table 1.
The part of ongoing clinical trials of cancer immunotherapy based on EV.
| ID | Sponsor | Tumor | Enrollment | Strategy | Phase/Status |
|---|---|---|---|---|---|
| Immunotherapy | |||||
| NCT01159288 | Gustave Roussy, Cancer Campus, Grand Paris | NSCLC | 41 | Cyclophosphamide and tumor antigen-loaded Dex | Phase 2/Complete |
| NCT03608631 | M.D. Anderson Cancer Center | Pancreas cancer | 28 | EVs With KrasG12D siRNA | Phase 1/Recruiting |
| NCT01550523 | Jefferson University | Recurrent malignant gliomas | 13 | EVs deliver tumor antigens, activate immune response | Phase 1/Complete |
| Diagnosis | |||||
| NCT03824275 | Columbia University | Prostate cancer | 300 | Diagnostic marker | Phase 2/3/Recruiting |
| NCT03228277 | Konkuk University Medical Center | NSCLC | 25 | Marker after treatment | Phase 2/Complete |
| NCT02977468 | Eileen Connolly | TNBC | 15 | Marker after treatment | Phase 1/Recruiting |
| Drug delivery | |||||
| NCT01294072 | University of Louisville | Colon cancer | 35 | Plant EVs Deliver Curcumin | Phase 1/Recruiting |
The data source: https://clinicaltrials.gov/. NSCLC, Non small cell lung cancer; TNBC, Three-negative breast cancer.